Boston Scientific, a major medical-device maker known for its heart and vascular products, has seen its stock slide recently. But analysts at UBS think the sell-off has gone too far. In a new note, the bank argues that the current share price reflects an overly pessimistic view of the company's future, effectively assuming that sales will shrink through 2029. That outlook, UBS says, doesn't match the reality of Boston Scientific's product pipeline.
What UBS sees that the market might be missing
The bank points to a slate of new heart-focused devices expected to hit the market in 2027 and 2028. These products, still in development, are designed to treat conditions like heart failure and arrhythmias. UBS believes these launches could drive high-single-digit revenue growth, a pace that would outpace the flat or declining sales that the current stock price seems to imply.
Boston Scientific has a history of bringing innovative devices to market, including pacemakers, defibrillators, and stents. The company's long-term growth targets have often been supported by new product cycles. In this case, UBS argues that the market is underestimating the potential of the next wave of heart devices, which could address large and growing patient populations.
Why the stock might be undervalued
When a stock's price falls, it can sometimes reflect genuine concerns about a company's business. But UBS's analysis suggests that Boston Scientific's decline is more about sentiment than fundamentals. The bank notes that the current valuation implies that the company's sales will contract over the next several years. That seems at odds with the expected launch of new products, which typically boost revenue as they gain adoption among hospitals and cardiologists.
Medical-device companies often see their stocks dip during periods when they are between major product launches. Investors may worry about competition from rivals or about regulatory hurdles. But UBS believes that Boston Scientific's pipeline is strong enough to overcome those concerns. The bank's view is that once the new devices are approved and begin to generate sales, the market will reassess the company's growth prospects.
What it means for investors
For everyday investors, this analysis highlights a common dynamic in the stock market: sometimes a company's share price can disconnect from its underlying business performance. When that happens, it can create opportunities for those who are willing to look past short-term noise.
Boston Scientific operates in the medical technology sector, which tends to be less sensitive to economic cycles than many other industries. Demand for heart devices is driven by patient needs, not by consumer spending or corporate budgets. That stability can make the stock appealing for long-term portfolios, especially when the price seems to ignore future growth.
However, it's important to remember that product timelines can slip. Regulatory approvals from the Food and Drug Administration (FDA) are never guaranteed, and delays can push expected revenue further into the future. Investors should also consider that other medical-device companies, such as Medtronic and Abbott Laboratories, are competing in similar areas. Market expectations can shift quickly, and a stock that looks cheap today could stay cheap if the pipeline fails to deliver.
The broader picture
Boston Scientific's situation is part of a larger trend in the healthcare sector. Many medical-device makers are investing heavily in next-generation technologies, including minimally invasive procedures and remote monitoring. These innovations could reshape how heart disease is treated, potentially expanding the market for devices like the ones Boston Scientific is developing.
UBS's call is a reminder that stock prices often reflect short-term fears rather than long-term potential. For investors who are comfortable with the risks, periods of pessimism can be a chance to buy into a company with a clear growth path. But as always, it pays to do your own research and consider how any investment fits into your overall strategy.
Boston Scientific is scheduled to report its next quarterly earnings in the coming weeks. That report could provide more clarity on the timeline for its new devices and whether the company is on track to meet its growth targets. Earnings season often brings surprises, and investors will be watching closely to see if the company's outlook matches UBS's optimistic view.
